3 Things In Biotech, May 22: Breast Cancer Disruption!

|
Includes: ABEO, FMI, IMMU, SGEN
by: Zach Hartman
Summary

Immunomedics eyes the finish for their ADC in breast cancer.

Foundation Medicine lays the groundwork for major testing landscape.

Abeona updated on Sanfilippo B.

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious.

Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research.

Immunomedics eyes the finish for their ADC in breast cancer

Company: Immunomedics (IMMU)

Therapy: Sacituzumab govitecan

Disease: Metastatic triple-negative breast cancer

News: IMMU announced that they have submitted a final application for approval for their antibody-drug conjugate sacituzumab govitecan in patients with metastatic, previously treated triple-negative breast cancer. IMMU based this filing on data obtained from a phase 1/2 trial that showed highly favorable efficacy, with licensing and other trials following shortly thereafter.

Looking forward: It is definitely aggressive for IMMU to pursue approval on the basis of such early-stage clinical data, but the response rates presented at SABCS were remarkable compared with historical findings, and the FDA has made it a point in recent years to grant conditional approval for strong response data in areas of high unmet need. So I wouldn't be too surprised if IMMU secures this approval. Overall, this sucks for Seattle Genetics (SGEN), which was forced to terminate a deal with IMMU last year.

Foundation Medicine lays the groundwork for major testing landscape

Company: Foundation Medicine (FMI)

Therapy: FoundationOne CDx

Disease: Various

News: FMI announced that the Centers for Medicare and Medicaid Services approved their FoundationOneCDx test for ADLT status, meaning that this test will be covered by Medicare and Medicaid. This molecular testing platform provides useful mutational analysis information across a wide variety of solid tumors, allowing clinicians to personalize treatment selection based on individual tumor findings.

Looking forward: Considering cancer is a disease of old age, the inclusion of this test in Medicare reimbursement is a bigger deal than it may seem at first glance. Without this group, FMI would be relying on private payers, cutting out a huge source of revenue. In order to have FoundationOne see widespread adoption in the oncology community, doctors need to know that their patients won't suffer undue financial burden just to get their tumors tested.

Abeona updated on Sanfilippo B

Company: Abeona Therapeutics (ABEO)

Therapy: ABO-101

Disease: Sanfilippo B syndrome

News: ABEO delivered a presentation of updated findings from their ongoing phase 1/2 trial investigating ABO-101 in patients with Sanfilippo B syndrome. ABO-101 is designed to correct the defective NAGLU gene that encodes an enzyme needed to process certain polysaccharides, leading to severe growth defects and other health problems. The first patient enrolled in cohort 1 demonstrated no evidence of liver damage or immune response to the pieces of viral vector used to deliver the gene therapy. Furthermore, as of 30 days post-treatment, NAGLU levels were normalized, with corresponding corrections in various clinical findings, such as liver size and levels of heparan sulfate.

Looking forward: Very interesting early data, providing a faint glimmer of efficacy and safety in a rare but challenging disease. Currently, there is no standard of care for Sanfilippo B syndrome, and gene therapies have been held up as the wave of the future for such inherited disorders. Of course, these data won't get the drug approved, not until there is stronger experience with the gene therapy. However, this is about as positive as you're going to get with such early findings!

Author's note: Thank you for taking some time out of your day to read some commentary on recent biotech happenings. I hope you'll consider leaving a comment or a question in the section below! This is one way in which Seeking Alpha is able to gauge the effectiveness of its writers and the platform. So if you want to keep seeing more editions of "3 Things," go ahead and participate!

As I mentioned above, I am now collaborating with Avisol Capital Partners on their Marketplace service known as the Total Pharma Tracker (TPT). Some of my work will be available to TPT subscribers either exclusively, or in advance. I will also collaborate in developing watchlists and other investment essentials. Please subscribe to TPT by clicking on this link - Total Pharma Tracker.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.